Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection

摘要

Dear Editor,According to the literature, the skin is approximately involved in 2%-20.4% of all COVID-19 patients.1,2 The most reported cutaneous manifestations are an exanthematous rash, urticaria, chickenpox-like vesicles, livedo reticularis, chilblain-like lesions, petechiae, and acute hemorrhagic edema of infancy.2 Different cases of pityriasis rosea (PR) and pityriasis rosea-like eruptions have been recently reported.1-10 These observations correspond to the fact that HHV-6 and HHV-7 (probable etiological agents of PR) can be reactivated by viruses of the coronavirus family, including SARS-CoV-2.4,6